ITP

DaVita Honors 54 Nephrology Nurses with DAISY Awards

Retrieved on: 
Jeudi, mai 9, 2024
DAISY, Kidney disease, Chamberlain University, FAAN, DaVita Inc., Immune thrombocytopenic purpura, ITP, Immunity (medical), Nursing, Heart, Idiopathic disease, Curriculum, Immune system, Family, Patient, Dialysis, Health, Empathy, Respect, Memory, Connect

DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide.

Key Points: 
  • The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide.
  • "Nurses are such a significant part of the health care workforce, and they are at the heart of the care we provide at DaVita," said Tina Livaudais, chief nursing officer for DaVita.
  • The kind of work the nurses at DaVita are called on to do every day epitomizes the purpose of the DAISY Award."
  • To learn more about how DaVita supports nurses throughout their careers, visit Careers.DaVita.com .

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
Jeudi, mai 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Jeudi, mai 9, 2024
MuSK protein, FDA, ARDA, IND, PDUFA, Medicine, Autoimmunity, Efgartigimod alfa, Glomerulonephritis, CMS, Inflammation, ITP, IIP, ALS, Alfa Romeo, C2, Therapy, Systemic scleroderma, Safety, Euronext, Nektar, DGF, Sjögren syndrome, CIDP, Biology, IL-6, Nektar Therapeutics, GMG, TED, File, MMN, Lupus nephritis, Kidney, AMR, Multifocal motor neuropathy, Patient, Congenital myasthenic syndrome, Immune system, Dermatomyositis, Growth, Amgen, Pharmaceutical industry

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • “We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy.
  • VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Retrieved on: 
Mardi, avril 23, 2024
FDA, DSM-IV codes, Prurigo nodularis, Fast track (FDA), Safety, Risk, ITP, Food, Thrombocytopenia, Orphan, Research and development, Development, Patient, Fatigue, Intracranial hemorrhage, LUNA, Asthma, Sanofi, Hematology, BTK, IgG4-related disease

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

Key Points: 
  • Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).
  • The safety profile of rilzabrutinib was consistent with that reported in previous studies.
  • LUNA 3 study met its primary endpoint demonstrating a significantly higher proportion of patients receiving rilzabrutinib achieved the primary endpoint of durable platelet response versus placebo.
  • This clinically and statistically significant result was achieved in a population of patients with primary ITP that had been refractory to prior therapy.

EXTRAORDINARY NURSES RECOGNIZED AT RECOVERY CENTERS OF AMERICA

Retrieved on: 
Mercredi, avril 10, 2024
DAISY, FAAN, Immune thrombocytopenic purpura, RCA, ITP, Humanities, Partnership, Idiopathic disease, Family, Patient, Immune system, Memory, Nursing

King of Prussia, PA, April 10, 2024 (GLOBE NEWSWIRE) -- Nurses at Recovery Centers of America (RCA) will soon be honored with The DAISY Award for Extraordinary Nurses ®.

Key Points: 
  • King of Prussia, PA, April 10, 2024 (GLOBE NEWSWIRE) -- Nurses at Recovery Centers of America (RCA) will soon be honored with The DAISY Award for Extraordinary Nurses ®.
  • The award is part of the DAISY Foundation's mission to recognize the extraordinary, compassionate nursing care they provide patients and families every day.
  • Yet these unsung heroes are seldom recognized for the super-human, extraordinary, compassionate work they do.
  • This evidence based, internationally recognized award demonstrates the value our nurses bring to the organization and the patients and families we serve.”

Sumitomo Mitsui Trust Asset Management Adopts DTCC’s ITP Services as Industry Prepares for U.S. Move to T+1

Retrieved on: 
Mercredi, avril 17, 2024
Fintech, Asset Management, Professional Services, Finance, DTC, SDA, NRI, ITP, ALERT, CTM, Depository Trust Company, Workflow, Automation, SSI, Security (finance)

Sumitomo Mitsui Trust Asset Management is the first Japanese asset management firm to adopt ITP services through Nomura Research Institute’s (NRI) SmartBridge Advance, an offering made possible through collaborative efforts between DTCC and NRI .

Key Points: 
  • Sumitomo Mitsui Trust Asset Management is the first Japanese asset management firm to adopt ITP services through Nomura Research Institute’s (NRI) SmartBridge Advance, an offering made possible through collaborative efforts between DTCC and NRI .
  • “We are pleased to adopt DTCC’s ITP suite of services,” said Yosuke Hosokawa, Sumitomo Mitsui Trust Asset Management.
  • Sumitomo Mitsui Trust Asset Management is the first regional asset management firm to utilize the soto-soto arrangement among DTCC’s ITP clients.
  • “We are pleased to partner with Sumitomo Mitsui Trust Asset Management to bring best practice capabilities that enable accelerated settlement in the region,” said Val Wotton, Managing Director and General Manager, DTCC Institutional Trade Processing.

Open Finance: Sicredi Uses Sensedia Solutions to Create Value for Members

Retrieved on: 
Jeudi, avril 11, 2024
Banking, Software, Professional Services, Internet, Business, Personal Finance, Fintech, Data Management, Payments, Electronic Commerce, Apps, Applications, Technology, Finance, Pix, Financial management, PFM, ITP, Personal, Partnership, Central Bank of Myanmar, API, Central bank, Payment, Growth

Sensedia today announced significant results from open finance initiatives with Sicredi, a Brazilian cooperative financial institution.

Key Points: 
  • Sensedia today announced significant results from open finance initiatives with Sicredi, a Brazilian cooperative financial institution.
  • Sicredi recognized and embraced the concept of open finance, integrating into the open ecosystem from its outset.
  • Fantinel shares that with the advent of open finance, Sicredi embarked on a journey to glean insights into its members' financial behaviors.
  • Also, to prioritize members' financial well-being, Sicredi implements alerts for situations when members inadvertently dip into overdrafts from other banks.

Notice Annual General Meeting of New Wave Group AB (publ)

Retrieved on: 
Jeudi, avril 11, 2024
Sport, Proxy, Companies Act, Person, ITP, Annual report, Audit, Committee, Consolidated, Remuneration, Employment, Marketing, Section 5, AGM

GOTHENBURG, Sweden, April 11, 2024 /PRNewswire/ -- The previously published notice contained erroneous information regarding the first dividend payment date. The notice below is updated with correct information.

Key Points: 
  • Shareholders should therefore notify the trustee of their wish to register their voting rights well in advance of this date.
  • Board members, the Managing Director and other persons of the executive management (jointly the "executive management") in New Wave Group AB (the "Company") fall within the provisions of these guidelines.
  • they are applicable to remuneration agreed, and amendments to remuneration already agreed, after adoption of the guidelines by the annual general meeting 2020.
  • The pension premiums for premium defined pension shall amount to not more than 30 percent of the fixed annual cash salary.

Notice Annual General Meeting of New Wave Group AB (publ)

Retrieved on: 
Mercredi, avril 10, 2024
Sport, Proxy, Companies Act, Person, ITP, Annual report, Audit, Committee, Consolidated, Remuneration, Employment, Marketing, Section 5, AGM

Board members, the Managing Director and other persons of the executive management (jointly the "executive management") in New Wave Group AB (the "Company") fall within the provisions of these guidelines.

Key Points: 
  • Board members, the Managing Director and other persons of the executive management (jointly the "executive management") in New Wave Group AB (the "Company") fall within the provisions of these guidelines.
  • they are applicable to remuneration agreed, and amendments to remuneration already agreed, after adoption of the guidelines by the annual general meeting 2020.
  • To ensure good risk diversification, the group will market its products in the promo market and the retail market.
  • The pension premiums for premium defined pension shall amount to not more than 30 percent of the fixed annual cash salary.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Mardi, mars 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.